ログアウト
ライト
ダーク
戻る
-
マーケット
-
注目機能
-
ニュース
-
Moo
-
学ぶ
-
もっと見る
- 日本語
- ダーク
- ライト
レプリミューンに関するコメント
NEWS
Replimune Group, Inc. announced positive interim results from the ARTACUS Phase 1/2 clinical trial evaluating RP1 monotherapy for skin cancers in transplant patients, showing a 34.8% overall response rate with good durability. The treatment was well-tolerated and resulted in immune activation.
The reason why I am interested in oncolytic virus is that the virus itself is a kind of drug, and at the same time, the virus can become the carrier of other drugs. This dual property is not possessed by other drugs at present, and it is up to us to fully exploit this function.$レプリミューン(REPL.US)$$キャンデル・セラピューティクス(CADL.US)$
まだコメントはありません